Allergic Rhinitis Pipeline Analysis Demonstrates Novel 35+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

Published February 17, 2023

DelveInsight’s, “Allergic Rhinitis Pipeline Insight, 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the Allergic Rhinitis pipeline drug profiles, including Allergic Rhinitis clinical trial and nonclinical stage products. It also covers the Allergic Rhinitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Allergic Rhinitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Allergic Rhinitis NDA approvals (if any), and product development activities comprising the technology, Allergic Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Allergic Rhinitis Pipeline Report

  • DelveInsight’s Allergic Rhinitis Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Allergic Rhinitis treatment.
  • The leading Allergic Rhinitis Companies are working to develop drug candidates to improve Allergic Rhinitis treatment landscape include Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals Inc., Revolo Biotherapeutics, Emergo Therapeutics, Advagene Biopharma, AOBiome LLC, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Siolta Therapeutics, Worg Pharmaceuticals, ABVC Biopharma, Revelation Biosciences,  Altamira Therapeutics, Qyuns Therapeutics, Dobecure, Funpep, GL Pharm Tech, Archivel Farma, Nasus Pharma, RIKEN, Paradigm Pharmaceuticals,  DC4U, United Biomedical, Marinomed Biotech, Desentum,  Roxall Medizin and others.
  • Promising Allergic Rhinitis Pipeline therapies in various stages of development include AI-201901, Injectable MPL allergy vaccine, REGN5713-5714-5715, House dust mite allergy immunotherapy, Birch pollen allergy vaccine tablet, B 244, AD 17002, CSPCHA-115, MM09-MG01, MG 01/T 517, IRL 201104, REVTx-99b, QX 005N, FPP004, GLF1MO, INI2004, RUTI, FMXIN002,   UB-211and others.
  • Allergic Rhinitis pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Explore more about the latest breakthroughs of the Allergic Rhinitis treatment landscape @ Allergic Rhinitis Pipeline Outlook Report 

Allergic Rhinitis Overview

Allergic rhinitis (AR) is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. It affects one in six individuals and is associated with significant morbidity, loss of productivity, and healthcare costs. Historically, Allergic rhinitis was thought to be a disease process of the nasal airway alone. Still, the development of the unified airway theory has classified AR as a component of systemic allergic response, with other associated conditions, such as asthma and atopic dermatitis, sharing an underlying systemic pathology. AR can be classified as either seasonal (intermittent) or perennial (chronic), with approximately 20% of cases being seasonal, 40% perennial, and 40% with features of both.

Recent Developmental Activities in the Allergic Rhinitis Treatment Landscape

  • In January 2022, Glenmark announced the approval of Ryaltris. Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients 12 years of age and older. Glenmark in January 2022 entered into licensing agreement with Lotus International wholly owned subsidiary of Lotus Pharmaceutical, for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong, and Vietnam.
  • In January 2022, Revelation Biosciences dosed and enrolled the first patient in a Phase Ib clinical study to evaluate the potential utility of REVTx-99 in treating patients with allergic rhinitis and patients with chronic nasal congestion without polyps. The clinical study is being conducted in Australia.
  • Paradigm Pharmaceuticals focus remains on exploring Pentosan Polysulfate Sodium (PPS) use in treating the myriad conditions that begin with and are sustained by inflammation. The company is evaluating the use of PPS in chronic heart failure (CHF), treating alphavirus induced arthralgia (in patients with Ross River Virus and Chikungunya); and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).
  • In May 2022, ABVC Biopharma announced that BioKey, a wholly-owned subsidiary of the company based in Fremont, California, entered into a $3.0 million clinical services contract with NeuCen BioMed Co. Ltd. to guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under US FDA IND regulatory requirements. CEN501 is a nasal strip product used as a local nasal immunotherapy (LNIT) for the treatment of mite-induced allergic rhinitis patients.
  • In March 2022, Altamira Therapeutics announced completion of patient enrollment in its Bentrio trial in house dust mite (“HDM”) allergic rhinitis. The Company expects to release top-line results from the trial during the second quarter of 2022.

Discover more information about allergic rhinitis emerging therapies and companies @ Allergic Rhinitis Treatment Landscape 

Allergic Rhinitis Emerging Drugs Profile

REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is a cocktail of three Bet v1 monoclonal antibodies. Regeneron Pharmaceuticals is investigating REGN5713-5714-5715 as intravenous injections in Phase III clinical studies for the treatment of allergic rhinitis and conjunctivitis.


Inmunotek is developing a subcutaneously administered immunotherapy product MM 09, containing biological extracts of house dust mite, designated as M 601 (MM09-MG01). A Phase III Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen has been initiated.

Allergic Rhinitis Therapeutics Assessment

There are approx. 35+ key companies which are developing the therapies for Allergic Rhinitis. The companies which have their Allergic Rhinitis drug candidates in the mid to advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals.

Learn more about the novel and emerging Allergic Rhinitis pipeline therapies @ Allergic Rhinitis Ongoing Clinical Trials Analysis 

Scope of the Allergic Rhinitis Pipeline Report

  • Coverage- Global
  • Allergic Rhinitis Companies- Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, Revelation Biosciences and others.
  • Allergic Rhinitis Pipeline Therapies- AI-201901, Injectable MPL allergy vaccine, REGN5713-5714-5715, House dust mite allergy immunotherapy, Birch pollen allergy vaccine tablet, B 244, AD 17002, CSPCHA-115, MM09-MG01, MG 01/T 517, REVTx-99b and others.
  • Allergic Rhinitis Segmentation: Phases, Molecule Type, Route of Administration, Mechanism of Action, Product Type

Table of Content

  1. Introduction
  2. Executive Summary
  3. Allergic Rhinitis: Overview
  4. Allergic Rhinitis Pipeline Therapeutics
  5. Allergic Rhinitis Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. REGN5713-5714-5715: Regeneron Pharmaceuticals
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. IRL201104: Revolo Biotherapeutics
  11. Pre-clinical and Discovery Stage Products
  12. Drug profiles in the detailed report…..
  13. Inactive Products
  14. Allergic Rhinitis Key Companies
  15. Allergic Rhinitis Key Products
  16. Allergic Rhinitis- Unmet Needs
  17. Allergic Rhinitis- Market Drivers and Barriers
  18. Allergic Rhinitis- Future Perspectives and Conclusion
  19. Allergic Rhinitis Analyst Views
  20. Allergic Rhinitis Key Companies
  21. Appendix

To learn more information about the Key Allergic Rhinitis Companies and Drugs, just visit @ Allergic Rhinitis Market Drivers and Barriers

Trending Market Research Reports in 2023 | DelveInsight

  1. Radiation Retinopathy Market
  2. Stem Cell Market
  3. UK Healthcare Report
  4. Oncolytic Virus Cancer Therapy Pipeline
  5. Vulvar Cancer Market
  6. Persistent Epithelial Defect Market
  7. Chronic Heart Failure Market
  8. Scabies Market
  9. UK Healthcare Outlook Report
  10. Shingles Market
  11. Medical Marijuana Market
  12. Brucellosis Market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States